CAR-T therapy has demonstrated remarkable efficacy in treating various hematological malignancies:
Acute Lymphoblastic Leukemia (B-ALL): For pediatric and adult patients with relapsed or refractory disease who have exhausted standard treatment options
Diffuse Large B-Cell Lymphoma (DLBCL): For patients who have failed two or more lines of systemic therapy, including chemotherapy and targeted agents
Multiple Myeloma: BCMA-targeted therapy for patients with relapsed or refractory disease after multiple prior treatments
Mantle Cell Lymphoma (MCL): For patients with relapsed or refractory disease following chemotherapy and BTK inhibitor therapy
Follicular Lymphoma (FL): For patients who have progressed after multiple lines of therapy including anti-CD20 antibodies
CD19\BCMA CAR-T therapy has demonstrated remarkable efficacy in treating various Autoimmune diseases：
Systemic Lupus Erythematosus (SLE) ：The primary culprits in SLE are B cells that produce autoantibodies. CAR-T cells are typically engineered to target CD19 (a marker on the surface of B cells), precisely clearing these pathogenic cells.
